

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Insolvency Services Group (ISG)	12/18/2012
RECEIVING PARTY DATA	
Name:	Synageva BioPharma Corp.
Street Address:	128 Spring Street
City:	Lexington
State/Country:	MASSACHUSETTS
Postal Code:	02421
PROPERTY NUMBERS Total: 9	
Property Type	Number
Application Number:	12105231
Application Number:	10524089
Application Number:	13550488
Application Number:	10104486
Application Number:	11977538
Application Number:	12896681
Application Number:	12835721
Application Number:	10104057
Application Number:	10508808
CORRESPONDENCE DATA	
Fax Number:	6176079218
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	6174496500
Email:	docket@mccarter.com
Correspondent Name:	McCarter & English, LLP
Address Line 1:	265 Franklin Street

CH \$360.00 12105231

Address Line 2: Maria Laccotripe Zacharakis, Ph.D., J.D.

Address Line 4: Boston, MASSACHUSETTS 02110

NAME OF SUBMITTER:

Maria Laccotripe Zacharakis, Ph.D., J.D.

Total Attachments: 5

source=Origen_Assignment#page1.tif

source=Origen_Assignment#page2.tif

source=Origen_Assignment#page3.tif

source=Origen_Assignment#page4.tif

source=Origen_Assignment#page5.tif

CONFIRMATORY ASSIGNMENT

WHEREAS, Insolvency Services Group, Inc., is a California Corporation (hereinafter the "Assignor") engaged in the business of providing certain insolvency-related services including, without limitation, acting as the assignee under general assignments for the benefit of creditors. Under the terms of that certain General Assignment dated June 6, 2012, Insolvency Services Group, Inc. accepted from Origen Therapeutics, Inc. an assignment of all rights, title and interest in and to the patents and patent applications listed in Appendix A attached herein (hereinafter the "Patent Rights");


WHEREAS, Synageva BioPharma Corp., a Delaware corporation, located at 128 Spring St., Lexington, Massachusetts 02421 (hereinafter "Assignee") and Assignor entered into an Asset Purchase Agreement dated July 30, 2012 (hereinafter the "Agreement") in which Assignor sold, transferred and assigned to Assignee all rights, title and interest in and to the Patent Rights; and

WHEREAS, Assignee desires to further memorialize the transfer of Assignor's entire right, title and interest in and to said Patent Rights for purposes of filing the same with the United States Patent and Trademark Office and other appropriate governmental offices.

NOW, THEREFORE, in consideration of the amount specified in the Agreement, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby confirms that the transfer and assignment to Assignee of the entire right, title and interest in and to the Patent Rights has occurred as of July 30, 2012. Assignor further agrees, for itself, its successors and assigns, to execute such further documents and to perform such further lawful acts as may reasonably be requested by Assignee to implement this assignment.

IN WITNESS WHEREOF, the parties have executed this Confirmatory Assignment as of the date first set forth below.

Insolvency Services Group, Inc.
Solely in its Capacity as Assignee for
The Benefit of Creditors of
Origen Therapeutics, Inc.

By: 

Title: CEO

Witness: 

Date: 12/18/12

Synageva BioPharma Corp.

By: 

Title: LEGAL COUNSEL

Witness: 

Date: 12/19/12

APPENDIX A

Family	Application Number	Patent Number	Title
1	AU 88485/98	750028	PRODUCTION OF PROTEINS IN EGGS
	CA 2311116		PRODUCTION OF PROTEINS IN EGGS
	FR 98940016.3	1007697	PRODUCTION OF PROTEINS IN EGGS
	DE 98940016.3	69837337.5	PRODUCTION OF PROTEINS IN EGGS
	HK 108066.2	1028623	PRODUCTION OF PROTEINS IN EGGS
	IE 98940016.3	1007697	PRODUCTION OF PROTEINS IN EGGS
	IR 134618	134618	PRODUCTION OF PROTEINS IN EGGS
	JP 2000-507813	4731683	PRODUCTION OF PROTEINS IN EGGS
	JP 2010-244106		PRODUCTION OF PROTEINS IN EGGS
	NZ 503098	503098	PRODUCTION OF PROTEINS IN EGGS
	UK 98940016.3	1007697	PRODUCTION OF PROTEINS IN EGGS
	US 09/486,215	6,861,572	PRODUCTION OF PROTEINS IN EGGS
	US 13/021674		PRODUCTION OF PROTEINS IN EGGS
	US 13/333870		PRODUCTION OF PROTEINS IN EGGS
2	CA 2495100		TISSUE SPECIFIC EXPRESSION OF EXOGENOUS PROTEINS IN TRANSGENIC CHICKENS
	EP 3785241.5		TISSUE SPECIFIC EXPRESSION OF EXOGENOUS PROTEINS IN TRANSGENIC CHICKENS

Family	Application Number	Patent Number	Title
	JP 2004-528087		TISSUE SPECIFIC EXPRESSION OF EXOGENOUS PROTEINS IN TRANSGENIC CHICKENS
	JP 2010-021678		TISSUE SPECIFIC EXPRESSION OF EXOGENOUS PROTEINS IN TRANSGENIC CHICKENS
	US 10/216098	7,323,618	TISSUE SPECIFIC EXPRESSION OF EXOGENOUS PROTEINS IN TRANSGENIC CHICKENS
	NZ 591706		TISSUE SPECIFIC EXPRESSION OF EXOGENOUS PROTEINS IN TRANSGENIC CHICKENS
	US 12/105,231		TISSUE SPECIFIC EXPRESSION OF EXOGENOUS PROTEINS IN TRANSGENIC CHICKENS
3	CA 2480012		CHIMERIC BIRD FROM EMBRIONIC STEM CELLS
	EP 3710832.1		CHIMERIC BIRD FROM EMBRIONIC STEM CELLS
	US 10/067148	7,145,057	CHIMERIC BIRD FROM EMBRIONIC STEM CELLS
4	AU 2006210645		TRANSGENIC CHICKENS (PGC DERIVED)
	AU 2012201824		TRANSGENIC CHICKENS (PGC DERIVED)
	CA 2595576		TRANSGENIC CHICKENS (PGC DERIVED)
	CN 200680010896		TRANSGENIC CHICKENS (PGC DERIVED)
	EP 6734219		TRANSGENIC CHICKENS (PGC DERIVED)
	IR 184775		TRANSGENIC CHICKENS (PGC DERIVED)
	NZ 587948		TRANSGENIC CHICKENS (PGC DERIVED)

Family	Application Number	Patent Number	Title
	NZ 598769		TRANSGENIC CHICKENS (PGC DERIVED)
	US 11/346630		TRANSGENIC CHICKENS (PGC DERIVED)
5	US 11/049229		LONG-TERM CULTURE OF AVIAN PRIMORDIAL GERM CELLS (PGCs)
6	AU 2006214003		TISSUE SPECIFIC EXPRESSION OF ANTIBODIES IN CHICKENS
	CA 2597837		TISSUE SPECIFIC EXPRESSION OF ANTIBODIES IN CHICKENS
	CN 200680012841.8		TISSUE SPECIFIC EXPRESSION OF ANTIBODIES IN CHICKENS
	EP 6735759		TISSUE SPECIFIC EXPRESSION OF ANTIBODIES IN CHICKENS
	IR 185097		TISSUE SPECIFIC EXPRESSION OF ANTIBODIES IN CHICKENS
	JP2007-556146		TISSUE SPECIFIC EXPRESSION OF ANTIBODIES IN CHICKENS
	US 11/062325		TISSUE SPECIFIC EXPRESSION OF ANTIBODIES IN CHICKENS
7	AU 2008286791		TRANSGENIC CHICKENS WITH AN INACTIVATED ENDOGENOUS GENE LOCUS
	CA 2706224		TRANSGENIC CHICKENS WITH AN INACTIVATED ENDOGENOUS GENE LOCUS
	CN 200880111586		TRANSGENIC CHICKENS WITH AN INACTIVATED ENDOGENOUS GENE LOCUS
	EP 08797925.8		TRANSGENIC CHICKENS WITH AN INACTIVATED ENDOGENOUS GENE LOCUS
	IR 203944		TRANSGENIC CHICKENS WITH AN INACTIVATED ENDOGENOUS GENE LOCUS

Family	Application Number	Patent Number	Title
	JP 2010-521188		TRANSGENIC CHICKENS WITH AN INACTIVATED ENDOGENOUS GENE LOCUS
	KR 10-2010-7005724		TRANSGENIC CHICKENS WITH AN INACTIVATED ENDOGENOUS GENE LOCUS
	NZ 583906		TRANSGENIC CHICKENS WITH AN INACTIVATED ENDOGENOUS GENE LOCUS
	US 12/192,020		TRANSGENIC CHICKENS WITH AN INACTIVATED ENDOGENOUS GENE LOCUS
8	US 11/204879		GERMLINE TRANSMISSION OF AVIAN PRIMORDIAL GERM CELLS
9	US 12/835721		TRANSGENIC AVES PRODUCING HUMAN POLYCLONAL ANTIBODIES
	US 10/104057		TRANSGENIC AVES PRODUCING HUMAN POLYCLONAL ANTIBODIES
10	US 13/281362		FUNCTIONAL DISRUPTION OF AN IMMUNOGLOBULIN GENE
	CA 2480018		FUNCTIONAL DISRUPTION OF AN IMMUNOGLOBULIN GENE
11	NZ 516958	516958	METHOD OF PRODUCING AN UNDIFFERENTIATED AVIAN CELL CULTURE USING AVIAN PGCs
12	US 61/530323		TRANSGENIC CHICKENS THAT PRODUCE CHIMERIC HUMAN IMMUNOGLOBULINS
	US 61/582260		TRANSGENIC CHICKENS THAT PRODUCE CHIMERIC HUMAN IMMUNOGLOBULINS